SRPT has been a mess for the last year. Yes the CEO has been a disaster in not following FDA protocol but this inexperienced board was never value-add in the company's development. Sadly emotions & bad decision making ran rampant. Why anyone would invest in a bad company not following the FDA process is beyond me.
Not even close---read into it anyway you want. Clearly you weren't in the meeting with management nor heard any of the Q&A. Diplomatic research note.
Clearly you were not in the meeting nor heard any of the Q&A. Peel the onion back on ACAD----not all is or has been going well. The new CEO is not at fault but the prior clowns sure did not run ACAD professionally at all---with more fallout likely to come. Sad.
You buy a stock off of "Stock Gumshoe" ???????? Unless you have lots of money to lose maybe get professional advice.
You ARE a newbie !! Maybe stay with mutual funds or ETFs. IBB may a good way for you to invest in biotechs. Companies like MEIP are likely way beyond your pay grade----you don't know management, the sector, the science. That stacks the odds against you big time.
More often than not you don't the access or the ability to handicap the information.
are you for real ? I bought AMR in bankruptcy and it's now $ 54.MEIP does not resemble AAL other than people guessing & losing $$.
VZ chose not to take CSCO $1 billion vendor financing but rather stay with incumbent 100G vendor CIEN on equal++ footing for CIEN. That bodes well for CIEN where there was a market concern that they would get a minority share of the contract with CSCO buying their way into the order. Fortunately VZ is looking at performance which tells us what they think of CIEN (+++).
you are off to the races ! any other prescient thoughts ???
S&P500 stocks are part of a basket of larger market cap stocks. As new $$ comes in or goes out of the market through index investing it affects the underlying shares. Both major and individual money participates in their equity holdings by participating in the S&P indices.
AAL will trade on its own metrics---economic outlook, management, cost of major items (fuel, labor), currencies (strong dollar curtails European travelers to the US this summer for example). AAL remains an attractive story---as management continues buyback, no fuel hedges in a declining energy outlook & dividend increases (which DAL has done).
DAL jumped 9.4% after the S&P 500 announcement. As important DAL outperformed the market by 780 basis points 30 days after its official inclusion. Maybe it can happen again to AAL ?? AAL still looks like it can post the largest operating margin increase of the majors in 2015---especially if jet fuel prices continue to head lower. AAL has a decent shot at the mid $60s this year.